Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	108.09B -61.0%
Revenue (ttm)	10.79B +2.9%
Net Income	606.40M -78.3%
EPS	2.35 -78.5%
Shares Out	382.57M
PE Ratio	120.25
Forward PE	37.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	907,550
Average Volume	1,729,607
Open	289.60
Previous Close	282.55
Day's Range	279.65 - 297.25
52-Week Range	266.70 - 1,250.00
Beta	0.15
RSI	30.23
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.